INSIGHTS ON DRUG DEVELOPMENT

• Evolving Gene Editing For Rare Disease Drug Development

  Explore how scalable gene editing platforms are advancing therapies for ultra-orphan conditions, with insights into manufacturing models, regulatory strategies, and clinical approaches.

• Overcoming Gene Therapy Cost Roadblocks On The Path To Patients

  Viral vector-based gene therapies are expanding beyond rare diseases to treat larger populations. Discover how innovations in manufacturing are making these life-changing treatments more accessible.

• Color Consistency In UHMWPE Medical Textiles

  Color consistency improves surgical visibility, differentiation, and workflow efficiency, requiring medical textiles that deliver strength, compliance, and reliable quality in every color.

• Alzheimer's Disease Pathway

  Alzheimer’s disease (AD) affects 50 million people globally, causing cognitive decline. Explore the signaling pathways of amyloid beta and tau proteins, linking them to neuronal death and AD symptoms.

• Lentiviral Vector Upstream Process

  12/12/2025

  Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.

• Improving In Vitro Cancer Modeling

  8/2/2024

  Organ-on-a-Chip technology represents a significant advancement in drug discovery. By mimicking human physiology, Organ-Chips can enhance the predictive accuracy of preclinical models and accelerate drug development.

• Injection Site Reaction Screening Methodology

  6/6/2025

  Optimize drug formulations for solubility at physiological pH to reduce injection site reactions, enable high-concentration dosing, and enhance patient comfort and compliance.

• Deciphering Nanoparticle Properties With AF4

  5/6/2026

  Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

• Data-Driven Strategies To De-Risk OSD Development

  6/17/2026

  Watch as Quentin Horgan, Director of Drugs Intelligence at GlobalData discusses how early-stage insights can improve development outcomes and reduce downstream risk.